{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T13:29:16Z","timestamp":1773408556150,"version":"3.50.1"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>The most common mechanism of azole (itraconazole and voriconazole) resistance in Aspergillus fumigatus is a mutation at the cyp51A locus. The aim of our study was to determine the rate of cyp51A mutations in lung transplant recipients (LTR) undergoing targeted antifungal prophylaxis with 12 weeks of voriconazole.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a prospective study that included 22 LTR with A. fumigatus between October 2008 and November 2011. Of those, 10 LTR were colonized with A. fumigatus and 12 had invasive pulmonary aspergillosis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Four patients were found to have A. fumigatus isolates with a cyp51A mutation, two had colonization and two had invasive pulmonary aspergillosis. The remaining 18 LTR had WT cyp51A A. fumigatus isolates. All A. fumigatus isolates (except one due to mixed growth) were tested for antifungal susceptibility. A total of nine LTR were exposed to azoles prior to A. fumigatus isolation for a median duration of 249 (IQR 99\u2013524) days. Azole exposure preceded the isolation of two mutant isolates and seven WT isolates. None of the cyp51A mutant isolates conferred phenotypic resistance to azoles.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Targeted antifungal prophylaxis in LTR did not lead to cyp51A resistance mutations in this cohort. Data on larger cohorts who receive universal antifungal prophylaxis are needed.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dku528","type":"journal-article","created":{"date-parts":[[2015,1,21]],"date-time":"2015-01-21T03:35:04Z","timestamp":1421811304000},"page":"1064-1067","source":"Crossref","is-referenced-by-count":16,"title":["Rate of <i>cyp51A<\/i> mutation in <i>Aspergillus fumigatus<\/i> among lung transplant recipients with targeted prophylaxis"],"prefix":"10.1093","volume":"70","author":[{"given":"S.","family":"Shalhoub","sequence":"first","affiliation":[{"name":"1 \u00a0Multi-Organ Transplant Program, University of Toronto, Toronto, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.-L.","family":"Luong","sequence":"additional","affiliation":[{"name":"1 \u00a0Multi-Organ Transplant Program, University of Toronto, Toronto, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. J.","family":"Howard","sequence":"additional","affiliation":[{"name":"2 \u00a0Division of Microbiology, University of Manchester, Manchester, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Richardson","sequence":"additional","affiliation":[{"name":"3 \u00a0Division of Microbiology, Hospital for Sick Children and Public Health Ontario Laboratories, Public Health Ontario, University of Toronto, Toronto, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. G.","family":"Singer","sequence":"additional","affiliation":[{"name":"1 \u00a0Multi-Organ Transplant Program, University of Toronto, Toronto, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Chaparro","sequence":"additional","affiliation":[{"name":"1 \u00a0Multi-Organ Transplant Program, University of Toronto, Toronto, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Keshavjee","sequence":"additional","affiliation":[{"name":"1 \u00a0Multi-Organ Transplant Program, University of Toronto, Toronto, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Akinlolu","sequence":"additional","affiliation":[{"name":"1 \u00a0Multi-Organ Transplant Program, University of Toronto, Toronto, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Rotstein","sequence":"additional","affiliation":[{"name":"1 \u00a0Multi-Organ Transplant Program, University of Toronto, Toronto, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Mazzulli","sequence":"additional","affiliation":[{"name":"3 \u00a0Division of Microbiology, Hospital for Sick Children and Public Health Ontario Laboratories, Public Health Ontario, University of Toronto, Toronto, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Husain","sequence":"additional","affiliation":[{"name":"1 \u00a0Multi-Organ Transplant Program, University of Toronto, Toronto, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2015,1,20]]},"reference":[{"key":"2022020120544750800_DKU528C1","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1086\/651262","article-title":"Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET)","volume":"50","author":"Pappas","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2022020120544750800_DKU528C2","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1056\/NEJM200212263472618","article-title":"Multidrug resistance in Aspergillus fumigatus","volume":"347","author":"Warris","year":"2002","journal-title":"N Engl J Med"},{"key":"2022020120544750800_DKU528C3","doi-asserted-by":"crossref","first-page":"4948","DOI":"10.1128\/AAC.05990-11","article-title":"Azole preexposure affects the Aspergillus fumigatus population in patients","volume":"56","author":"Alanio","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2022020120544750800_DKU528C4","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1128\/AAC.48.7.2747-2750.2004","article-title":"Substitutions at methionine 220 in the 14\u03b1-sterol demethylase (Cyp51A) of Aspergillus fumigatus are responsible for resistance in vitro to azole antifungal drugs","volume":"48","author":"Mellado","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"2022020120544750800_DKU528C5","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1093\/cid\/cir179","article-title":"High-frequency triazole resistance found in nonculturable Aspergillus fumigatus from lungs of patients with chronic fungal disease","volume":"52","author":"Denning","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2022020120544750800_DKU528C6","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/jac\/dkq450","article-title":"Low prevalence of resistance to azoles in Aspergillus fumigatus in a French cohort of patients treated for haematological malignancies","volume":"66","author":"Alanio","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"2022020120544750800_DKU528C7","doi-asserted-by":"crossref","first-page":"4465","DOI":"10.1128\/AAC.00185-11","article-title":"Azole resistance in Aspergillus fumigatus isolates from the ARTEMIS global surveillance study is primarily due to the TR\/L98H mutation in the cyp51A gene","volume":"55","author":"Lockhart","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2022020120544750800_DKU528C8","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1128\/JCM.00854-09","article-title":"Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the Transplant-Associated Infection Surveillance Network","volume":"47","author":"Baddley","year":"2009","journal-title":"J Clin Microbiol"},{"key":"2022020120544750800_DKU528C9","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","article-title":"Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2022020120544750800_DKU528C10","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N Engl J Med"},{"key":"2022020120544750800_DKU528C11","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.3201\/eid1507.090043","article-title":"Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure","volume":"15","author":"Howard","year":"2009","journal-title":"Emerg Infect Dis"},{"key":"2022020120544750800_DKU528C12","volume-title":"Reference Method for Broth Microdilution Antifungal Susceptibility Testing of Filamentous Fungi\u2014Second Edition: Approved Standard M38-A2","author":"Clinical and Laboratory Standards Institute","year":"2008"},{"key":"2022020120544750800_DKU528C13","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.1128\/AAC.00167-13","article-title":"cyp51A-based mechanisms of Aspergillus fumigatus azole drug resistance present in clinical samples from Germany","volume":"57","author":"Bader","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2022020120544750800_DKU528C14","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/myc.12089","article-title":"Environmental study of azole-resistant Aspergillus fumigatus with TR34\/L98H mutations in the cyp51A gene in Iran","volume":"56","author":"Badali","year":"2013","journal-title":"Mycoses"},{"key":"2022020120544750800_DKU528C15","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/AAC.05088-11","article-title":"Rapid induction of multiple resistance mechanism in Aspergillus fumigatus during azole therapy: a case study and review of the literature","volume":"56","author":"Camps","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2022020120544750800_DKU528C16","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1128\/AAC.00156-08","article-title":"Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus","volume":"52","author":"Rodriguez-Tudela","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2022020120544750800_DKU528C17","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1128\/AAC.47.3.1120-1124.2003","article-title":"A point mutation in the 14\u03b1-sterol demethylase gene cyp51A contributes to itraconazole resistance in Aspergillus fumigatus","volume":"47","author":"Diaz-Guerra","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"2022020120544750800_DKU528C18","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1128\/AAC.01092-06","article-title":"A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations","volume":"51","author":"Mellado","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"2022020120544750800_DKU528C19","doi-asserted-by":"crossref","first-page":"E278","DOI":"10.1111\/1469-0691.12148","article-title":"EUCAST technical note on voriconazole and Aspergillus spp","volume":"19","author":"Hope","year":"2013","journal-title":"Clin Microbiol Infect"},{"key":"2022020120544750800_DKU528C20","doi-asserted-by":"crossref","first-page":"e72280","DOI":"10.1371\/journal.pone.0072280","article-title":"Composite survival index to compare virulence changes in azole-resistant Aspergillus fumigatus clinical isolates","volume":"8","author":"Mavridou","year":"2013","journal-title":"PLoS One"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/70\/4\/1064\/42355515\/jac_70_4_1064.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/70\/4\/1064\/42355515\/jac_70_4_1064.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T21:00:44Z","timestamp":1643749244000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/70\/4\/1064\/807939"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,20]]},"references-count":20,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2015,1,20]]},"published-print":{"date-parts":[[2015,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dku528","relation":{},"ISSN":["1460-2091","0305-7453"],"issn-type":[{"value":"1460-2091","type":"electronic"},{"value":"0305-7453","type":"print"}],"subject":[],"published-other":{"date-parts":[[2015,4]]},"published":{"date-parts":[[2015,1,20]]}}}